Q1 EPS Estimates for CVS Health Reduced by Leerink Partnrs

CVS Health Co. (NYSE:CVS) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for CVS Health in a report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now anticipates that the pharmacy operator will post earnings of $1.41 per share for the quarter, down from their previous forecast of $1.49. The consensus estimate for CVS Health’s current full-year earnings is $6.18 per share. Leerink Partnrs also issued estimates for CVS Health’s Q2 2025 earnings at $1.64 EPS, Q4 2025 earnings at $1.68 EPS and FY2025 earnings at $6.65 EPS.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. During the same period in the previous year, the business earned $2.21 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis.

Several other research firms have also weighed in on CVS. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $68.00 price target on shares of CVS Health in a report on Wednesday, September 4th. Truist Financial upped their price objective on CVS Health from $66.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, October 11th. TD Cowen raised shares of CVS Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $59.00 to $85.00 in a report on Friday, October 4th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $62.00 price objective on shares of CVS Health in a report on Tuesday, October 1st. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $73.00.

CVS Health Trading Down 2.7 %

CVS Health stock opened at $55.54 on Friday. CVS Health has a 1 year low of $52.77 and a 1 year high of $83.25. The firm’s 50-day moving average is $59.56 and its 200-day moving average is $59.19. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.80. The company has a market cap of $69.87 billion, a P/E ratio of 14.10, a PEG ratio of 0.94 and a beta of 0.55.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were paid a dividend of $0.665 per share. The ex-dividend date was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.79%. CVS Health’s dividend payout ratio is currently 67.51%.

Institutional Investors Weigh In On CVS Health

Several hedge funds and other institutional investors have recently bought and sold shares of CVS. Norden Group LLC grew its position in CVS Health by 10.7% in the first quarter. Norden Group LLC now owns 6,830 shares of the pharmacy operator’s stock worth $545,000 after buying an additional 660 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of CVS Health in the 1st quarter worth $536,000. Advisory Alpha LLC raised its position in shares of CVS Health by 9.6% during the first quarter. Advisory Alpha LLC now owns 3,753 shares of the pharmacy operator’s stock worth $299,000 after purchasing an additional 329 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of CVS Health by 15.8% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 148,361 shares of the pharmacy operator’s stock valued at $11,833,000 after purchasing an additional 20,264 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of CVS Health by 341.8% in the 1st quarter. SG Americas Securities LLC now owns 203,103 shares of the pharmacy operator’s stock valued at $16,199,000 after purchasing an additional 157,133 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.